The Oncology Institute, Inc. - Common Stock (TOI)

Oncology Institute (TOI) beat Q3 2025 revenue forecasts and raised its full-year guidance, driving a 17.5% stock surge despite a wider quarterly loss.

The Oncology Institute (TOI) Q3 2025 Earnings Call

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Can Oncology Institute's stock continue rewarding investors?

San Francisco, CA – October 3, 2025 – In a move set to redefine the landscape of radiation oncology, Leo Cancer Care officially introduced its groundbreaking Upright Photon Therapy System, "Grace," at the ASTRO 2025 meeting in San Francisco on September 28, 2025. This innovative system challenges decades of conventional practice by

The Oncology Institute (TOI) reported Q2 2025 revenue of $119.8M, beating estimates, but EPS missed. Shares fell 4.6% on wider losses. Growth driven by pharmacy sales, but profitability challenges remain.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.